-$0.46 EPS Expected for Natera, Inc. (NTRA) This Quarter
Equities research analysts expect Natera, Inc. (NASDAQ:NTRA) to post ($0.46) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Natera’s earnings, with estimates ranging from ($0.50) to ($0.44). Natera posted earnings per share of ($0.50) in the same quarter last year, which would indicate a positive year over year growth rate of 8%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 8th.
On average, analysts expect that Natera will report full year earnings of ($2.02) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.96). For the next financial year, analysts forecast that the company will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.30) to ($1.18). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The company had revenue of $53.60 million for the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the previous year, the company earned ($0.46) EPS. Natera’s quarterly revenue was up 3.1% compared to the same quarter last year.
NTRA has been the subject of several recent research reports. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. ValuEngine lowered Natera from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. BidaskClub lowered Natera from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Cowen and Company reissued a “buy” rating and set a $14.00 price objective on shares of Natera in a research report on Friday, September 1st. Finally, Morgan Stanley lowered their price objective on Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Natera presently has a consensus rating of “Hold” and an average target price of $14.45.
In other Natera news, insider Jonathan Sheena sold 120,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the completion of the transaction, the insider now owns 533,208 shares of the company’s stock, valued at $6,686,428.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.57% of the company’s stock.
A number of institutional investors have recently made changes to their positions in NTRA. Teachers Advisors LLC lifted its position in Natera by 5.0% during the fourth quarter. Teachers Advisors LLC now owns 44,224 shares of the medical research company’s stock valued at $518,000 after buying an additional 2,116 shares during the period. Nationwide Fund Advisors lifted its position in Natera by 7.3% during the first quarter. Nationwide Fund Advisors now owns 62,273 shares of the medical research company’s stock valued at $552,000 after buying an additional 4,246 shares during the period. Prudential Financial Inc. lifted its position in Natera by 185.9% during the first quarter. Prudential Financial Inc. now owns 73,820 shares of the medical research company’s stock valued at $654,000 after buying an additional 48,000 shares during the period. American International Group Inc. lifted its position in Natera by 7.1% during the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares during the period. Finally, Alliancebernstein L.P. lifted its position in Natera by 5.6% during the first quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock valued at $236,000 after buying an additional 1,400 shares during the period. 59.79% of the stock is owned by institutional investors and hedge funds.
Natera (NASDAQ NTRA) traded up 5.38% on Wednesday, hitting $12.93. 231,249 shares of the company were exchanged. The company’s market capitalization is $688.17 million. Natera has a 52 week low of $7.88 and a 52 week high of $13.49. The stock has a 50 day moving average of $13.02 and a 200 day moving average of $13.02.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.